This month, Novartis submitted a letter to the FDA in support of a citizen petition that Pfizer filed in August.
This month, Novartis submitted a letter to the FDA in support of a citizen petition that Pfizer filed in August.
Pfizer’s citizen petition called on the agency to issue guidance clarifying how drug sponsors may communicate about biosimilars, alleging that misinformation communicated to patients, payers, and prescribers, is hindering the growth of the US biosimilar market.
In its comment letter, Novartis explained that it supports the recent efforts from the FDA and HHS to increase the use of biosimilars, specifically, releasing the Biosimilar Action Plan, holding a public hearing in September 2018, and initiating dialogue around key biosimilar topics through the American Patients First blueprint. However, Novartis notes that it believes the FDA and HHS “could do more to incentivize the use of biosimilars while still ensuring access to and development of novel biological products.”
The letter goes on to discuss the importance of accurate information about biosimilars being disseminated to the public, sharing in Pfizer’s concern, and specifically calling on the FDA and HHS to address multiple “misinformation campaigns” that it believes are hurting biosimilar uptake.
Novartis states that the following misinformation campaigns do not provide balanced information about biosimilar products “but rather infer potential risks and aim at casting doubts about their safety or efficacy”:
The letter also cited results seen in a recent report from FirstWord Pharma that found that 33% of respondents said they had heard negative feedback about biosimilars. “There appears to be a particular strategy among some originator companies to openly question the quality of biosimilars, in addition to negative discussion about their efficacy and safety,” concluded the report.
In order to address these issues, Novartis agreed with Pfizer on the need for additional FDA action and oversight “to help ensure a truthful environment exists within which healthcare providers and patients can make treatment decisions without harmful misinformation about biosimilars.”
Specifically, Novartis recommends that the FDA take the following actions: partner with the Federal Trade Commissioner to identify and address these campaigns, issue correspondence directing these organizations to stop publishing misinformation campaigns, establish a public list of which companies or organizations are conducting such campaigns, and enhance educational outreach efforts to contest the campaigns.
Finally, Novartis encouraged the FDA to publish a “Facts About Biosimilars” page on its website to address the most common misinformation and misunderstood elements about biosimilars. In order to deliver the content to a broader audience, Novartis suggested that the FDA work with and leverage relationships with healthcare provider organizations as well as patient advocacy organizations to ensure their members have access to it.
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
October 7th 2024The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.